Auxilius’ Post

As 2024 is underway, the life science sector faces great growth opportunity along with new industry norms. Products are on the precipice for commercial launch, organizations must stay judicious in capital allocation, and teams face new demands for resource efficiency - specifically around R&D spend and clinical accruals. Auxilius summarizes some observed trends here - check it out! https://hubs.li/Q02nlrn70

Clinical trials remain a costly and time-consuming process due to age-old industry challenges like recruitment and supply chain optimization, as well as those stemming from new medical innovations, competition from emerging players, and an exponential increase in data. In our most recent POV 👇 https://bit.ly/4aXOvSl David Ghesquieres explores how life sciences organizations can leverage powerful new digital and data capabilities and new trial designs to increase program efficiency, speed, and access.

What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:

What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:

Gain an edge with exclusive insights and benchmarks from our 2023 benchmarking study, based on the alignment design and refinement practices of 28 US life science organizations. Regularly evaluate and adapt territory alignment processes to account for changes in business dynamics and growth to eliminate the inefficiencies.      Explore the key findings now: https://lnkd.in/gRebSyqy #AlignmentDesign #StrategicInsights #LifeSciences #Benchmarking

What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:

What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:

What an extraordinary historical moment we are living in; every day technology is showing us new horizons and new opportunities. Today during the second edition of the Schulthess Forum: Life Sciences Day (https://lnkd.in/eiYe8-Qy) the various speakers-whom I thank-highlighted lights and shadows in the context of the pharmaceutical industry. Ahead of us lies enormous potential to be tapped, perhaps enriched by having had to go through a pandemic event that has pushed not only digitization but also our habits to a new level. A more pragmatic approach and adaptability to try to anticipate situations, even complex ones, and not just react. To paraphrase Steve Jobs; stay curious and stay ahead!